BioCentury | Aug 10, 2015
Finance

And then there were two

...page 7). Their peers all have been acquired after achieving varying degrees of success, including CuraGen Corp....
BioCentury | Oct 18, 2014
Company News

VC tracks

...principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp....
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...NASDAQ:CRA) Deal to discover/develop anti-cancer therapeutics using ADC Mutually terminated in 2008 ND ND 2004 CuraGen Corp....
BioCentury | Feb 22, 2010
Company News

Celldex, TopoTarget deal

...and India. In 2008, TopoTarget reacquired ex-European rights to the histone deacetylase (HDAC) inhibitor from CuraGen Corp....
...all sublicense revenues up to $6 million that TopoTarget receives from territories formerly licensed to CuraGen...
BioCentury | Feb 8, 2010
Company News

Spectrum Pharmaceuticals, Topotarget deal

...gives it 2-3 years of cash. TopoTarget reacquired ex-European rights to belinostat in 2008 from CuraGen Corp....
...up to $6 million in potential milestones. Celldex Therapeutics Inc. (NASDAQ:CLDX, Needham, Mass.) later acquired CuraGen...
BioCentury | Dec 21, 2009
Clinical News

CDX-011: Phase II data

...I portion of the trial (see BioCentury, June 8). Celldex received CDX-011 when it acquired CuraGen Corp....
BioCentury | Dec 7, 2009
Finance

Ebb & Flow

...tracks Tim Shannon joined Canaan Partners as venture partner. He was president and CEO of CuraGen Corp....
...group Connecticut Innovations as a managing director. He previously was EVP, treasurer and CFO at CuraGen Corp....
BioCentury | Oct 5, 2009
Company News

Celldex, CuraGen deal

...Celldex completed its previously announced acquisition of fellow cancer company CuraGen for about $93.5 million in...
...$93.5 million in a stock (see BioCentury, June 1). Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. CuraGen Corp....
BioCentury | Jun 8, 2009
Clinical News

CR011-vcMMAE: Additional Phase I/II data

...year (see BioCentury, Nov. 10, 2008). CuraGen's CR011-vcMMAE uses antibody-drug conjugate technology from Seattle Genetics. CuraGen Corp....
BioCentury | Jun 8, 2009
Clinical News

Vilazodone: Preliminary Phase I/II data

...weeks. The trial is continuing to enroll patients at 1.88 mg/kg CR011-vcMMAE every 3 weeks. CuraGen's...
Items per page:
1 - 10 of 404
BioCentury | Aug 10, 2015
Finance

And then there were two

...page 7). Their peers all have been acquired after achieving varying degrees of success, including CuraGen Corp....
BioCentury | Oct 18, 2014
Company News

VC tracks

...principal on the healthcare team. Shannon joined Canaan in 2009 after serving as CEO of CuraGen Corp....
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...NASDAQ:CRA) Deal to discover/develop anti-cancer therapeutics using ADC Mutually terminated in 2008 ND ND 2004 CuraGen Corp....
BioCentury | Feb 22, 2010
Company News

Celldex, TopoTarget deal

...and India. In 2008, TopoTarget reacquired ex-European rights to the histone deacetylase (HDAC) inhibitor from CuraGen Corp....
...all sublicense revenues up to $6 million that TopoTarget receives from territories formerly licensed to CuraGen...
BioCentury | Feb 8, 2010
Company News

Spectrum Pharmaceuticals, Topotarget deal

...gives it 2-3 years of cash. TopoTarget reacquired ex-European rights to belinostat in 2008 from CuraGen Corp....
...up to $6 million in potential milestones. Celldex Therapeutics Inc. (NASDAQ:CLDX, Needham, Mass.) later acquired CuraGen...
BioCentury | Dec 21, 2009
Clinical News

CDX-011: Phase II data

...I portion of the trial (see BioCentury, June 8). Celldex received CDX-011 when it acquired CuraGen Corp....
BioCentury | Dec 7, 2009
Finance

Ebb & Flow

...tracks Tim Shannon joined Canaan Partners as venture partner. He was president and CEO of CuraGen Corp....
...group Connecticut Innovations as a managing director. He previously was EVP, treasurer and CFO at CuraGen Corp....
BioCentury | Oct 5, 2009
Company News

Celldex, CuraGen deal

...Celldex completed its previously announced acquisition of fellow cancer company CuraGen for about $93.5 million in...
...$93.5 million in a stock (see BioCentury, June 1). Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. CuraGen Corp....
BioCentury | Jun 8, 2009
Clinical News

CR011-vcMMAE: Additional Phase I/II data

...year (see BioCentury, Nov. 10, 2008). CuraGen's CR011-vcMMAE uses antibody-drug conjugate technology from Seattle Genetics. CuraGen Corp....
BioCentury | Jun 8, 2009
Clinical News

Vilazodone: Preliminary Phase I/II data

...weeks. The trial is continuing to enroll patients at 1.88 mg/kg CR011-vcMMAE every 3 weeks. CuraGen's...
Items per page:
1 - 10 of 404